283 related articles for article (PubMed ID: 15208653)
1. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
Pawar SA; Szentirmay MN; Hermeking H; Sawadogo M
Oncogene; 2004 Aug; 23(36):6125-35. PubMed ID: 15208653
[TBL] [Abstract][Full Text] [Related]
2. Loss of USF transcriptional activity in breast cancer cell lines.
Ismail PM; Lu T; Sawadogo M
Oncogene; 1999 Sep; 18(40):5582-91. PubMed ID: 10523835
[TBL] [Abstract][Full Text] [Related]
3. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
4. The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells.
Szentirmay MN; Yang HX; Pawar SA; Vinson C; Sawadogo M
J Biol Chem; 2003 Sep; 278(39):37231-40. PubMed ID: 12857727
[TBL] [Abstract][Full Text] [Related]
5. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
Chang JT; Yang HT; Wang TC; Cheng AJ
Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
[TBL] [Abstract][Full Text] [Related]
6. Isolation and initial characterization of the BRCA2 promoter.
Davis PL; Miron A; Andersen LM; Iglehart JD; Marks JR
Oncogene; 1999 Oct; 18(44):6000-12. PubMed ID: 10557089
[TBL] [Abstract][Full Text] [Related]
7. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
8. USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry.
Moriuchi M; Moriuchi H; Margolis DM; Fauci AS
J Immunol; 1999 May; 162(10):5986-92. PubMed ID: 10229837
[TBL] [Abstract][Full Text] [Related]
9. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
10. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter.
Bouchard C; Dittrich O; Kiermaier A; Dohmann K; Menkel A; Eilers M; Lüscher B
Genes Dev; 2001 Aug; 15(16):2042-7. PubMed ID: 11511535
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.
Swarbrick A; Akerfeldt MC; Lee CS; Sergio CM; Caldon CE; Hunter LJ; Sutherland RL; Musgrove EA
Oncogene; 2005 Jan; 24(3):381-9. PubMed ID: 15489884
[TBL] [Abstract][Full Text] [Related]
13. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis.
Barsyte-Lovejoy D; Lau SK; Boutros PC; Khosravi F; Jurisica I; Andrulis IL; Tsao MS; Penn LZ
Cancer Res; 2006 May; 66(10):5330-7. PubMed ID: 16707459
[TBL] [Abstract][Full Text] [Related]
14. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.
Yang W; Shen J; Wu M; Arsura M; FitzGerald M; Suldan Z; Kim DW; Hofmann CS; Pianetti S; Romieu-Mourez R; Freedman LP; Sonenshein GE
Oncogene; 2001 Mar; 20(14):1688-702. PubMed ID: 11313917
[TBL] [Abstract][Full Text] [Related]
15. Upstream stimulatory factor regulates E box-dependent PAI-1 transcription in human epidermal keratinocytes.
Allen RR; Qi L; Higgins PJ
J Cell Physiol; 2005 Apr; 203(1):156-65. PubMed ID: 15372465
[TBL] [Abstract][Full Text] [Related]
16. Opposite transcriptional activity between the wild type c-myc gene coding for c-Myc1 and c-Myc2 proteins and c-Myc1 and c-Myc2 separately.
Batsché E; Crémisi C
Oncogene; 1999 Oct; 18(41):5662-71. PubMed ID: 10523846
[TBL] [Abstract][Full Text] [Related]
17. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
18. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells.
Kim DW; Gazourian L; Quadri SA; Romieu-Mourez R; Sherr DH; Sonenshein GE
Oncogene; 2000 Nov; 19(48):5498-506. PubMed ID: 11114727
[TBL] [Abstract][Full Text] [Related]
19. c-Myc does not require max for transcriptional activity in PC-12 cells.
Ribon V; Leff T; Saltiel AR
Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
[TBL] [Abstract][Full Text] [Related]
20. Expression of the TAF4b gene is induced by MYC through a non-canonical, but not canonical, E-box which contributes to its specific response to MYC.
Teye K; Okamoto K; Tanaka Y; Umata T; Ohnuma M; Moroi M; Kimura H; Tsuneoka M
Int J Oncol; 2008 Dec; 33(6):1271-80. PubMed ID: 19020761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
